ArticleThe New England journal of medicine2017
Crizanlizumab in Sickle Cell Disease.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05530239 (Single-center Pilot Study), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)
Who cites it
17 citing papers in PubMed.
- Review
- Distinct endothelial cells in chronic thromboembolic pulmonary hypertension.NPJ cardiovascular health · 2025Article
- Fostering a healthier generation of children with sickle cell disease through advancements in care.Pediatric research · 2025Review
- Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition.Haematologica · 2025Article
- Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.International journal of molecular sciences · 2024Review
- Classical Haematology: Dynamic Development at the Interface of Transfusion Medicine and Haematology.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Article
- The clinical spectrum of HbSC sickle cell disease-not a benign condition.British journal of haematology · 2024Article
- Gene therapy for sickle cell disease: where we are now?Hematology. American Society of Hematology. Education Program · 2021Article
- The gut microbiome in sickle cell disease: Characterization and potential implications.PloS one · 2021Article
- Treating sickle cell anemia.Science (New York, N.Y.) · 2020Article
- Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises.Cytokine · 2020Article
- Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.Frontiers in pediatrics · 2020Review
- Sickle cell disease: a review for the internist.Internal and emergency medicine · 2019Review
- Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.Journal of clinical medicine · 2019Review
- Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.Haematologica · 2019Article
- Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.Journal of blood medicine · 2019Article
- New Therapeutic Options for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2019Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28467874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.